imcl

This post is part of a feature in which we wonder whatever happened to some notorious financial felons. See all 17.

I sometimes get the impression that people think I'm joking when I say I love Martha Stewart. I get it; I don't look like I have much in common with Martha. My apartment is cluttered, my cleaning habits are slapdash at best, and my hair is generally unkempt. I have at least a week's worth of random garbage traveling with me in the Hyundai at all times -- and I often get the distinct impression that people from New England are looking down on me.

Despite our differences, Martha is a personal hero of mine. Flipping through her magazine, Martha Stewart Living, is not unlike paging through a National Geographic. It's a glossy, impeccably photographed glimpse into an exotic world that I can only hope one day to visit. If the July 2007 issue can be believed, Martha is the type of woman who, on a whim, jaunts out to East Hampton for a weekend of kayaking and antiquing. In between horseback rides and hikes, she just might whip up some pasta with salted pressed fish roe, or perhaps a nice avocado gelato. Can you imagine?

So you can appreciate my shock upon discovering that Martha, this creature of uncommon refinement, might also be a common white-collar criminal. On December 27, 2001, Stewart dumped 3,928 shares of ImClone Systems (NASDAQ: IMCL) through her broker, Peter Bacanovic of Merrill Lynch. Martha -- the CEO herself of an eponymous multi-million-dollar media empire, Martha Stewart Living Omnimedia (NYSE: MSO) -- raked in about $288,000 from the sale. The next day, after the market closed, ImClone announced that its cancer drug Erbitux had been rejected by the Food & Drug Administration. It was an explosive bit of news that sent ImClone shares plunging.

In the News:
Keeping Customers in a Crummy Economy
With recession expectations growing, some companies are taking extraordinary steps to hold on to customers. Telephone companies' offers for two months of free service and reduced rates, discounted gym membership renewals, and generous gift cards from high-end department stores all underscore a pervasive fear on Main Street: With the uncertainty around the credit seize-up, consumers may be digging in for a long hibernation.
http://www.businessweek.com/investor/content/oct2008/pi2008103_779103.htm?campaign_id=twxa

Why Do Failed CEOs Keep Getting Rehired?
Poor stock performance? Weak sales? No matter! If you were once a C.E.O., you can surely be one again. Failed CEOs like Home Depot's Bob Nardelli who ended up at Chrysler and American Airlines' Don Carty who is leading Virgin Atlantic failed CEOs regularly end up at the helm of other companies. Here's why.
http://www.portfolio.com/executives/features/2008/10/05/Why-Failed-CEOs-Get-Rehired

U.S. stock futures fell Monday morning, indicating a sharply lower open on Wall Street as the world's financial crisis rather than get a boost from the $700 billion rescue plan, seemed to have deepened in Europe. This as well as economic fears depressed world markets. Most major global markets plunged at least over 4%.

Wachovia Corp. (NYSE: WB) -- After a lower court decided in favor of Citigroup (NYSE: C), a state appeals court blocked the ruling late Sunday night, thus tilting the battle over Wachovia in favor of Wells Fargo (NYSE: WFC). Both banks want Wachovia for its deposits and branches. Despite that, WB shares are down about 18% in pre-market trade, WFC's down 2.7% and C's down 3.7%.

Bank of America (NYSE: BAC) -- a subsidiary has agreed to modify loans to tens of thousands of borrowers -- previously Countrywide Financial clients -- in 11 states that would enable them to keep their homes, or even help them move to a new home. If all 50 states were to join, the settlement could provide $8.7 billion in relief to 400,000 borrowers. BAC shares are down 4.3% in pre-market action.

National City Corp. (NYSE: NCC) shares are down over 22% in pre-market action as its debt was downgraded by Fitch Ratings.

5 Ways to Play the Stock Market's Wild Ride
Wall Street is in perpetual turmoil. Investors don't have to be.
http://www.cnbc.com/id/26973429

Credit Card Debt Could Be Next Shot to Rip Through Economy
Credit-card debt is on the brink of imploding and will be the next storm to hit the fragile finance industry, an investment research firm predicted this week.
http://www.marketwatch.com/news/story/bad-credit-card-debt-could-next/story.aspx?guid=%7BDE0C0B15%2D4760%2D491C%2DA0F4%2DD34CBD96F7B7%7D

U.S. stock futures were flat to lower Thursday morning following the senate approval of its version of the $700 billion bailout package. Meanwhile, the Federal Reserve said it was considering a rate cut. Following all the economic data released Wednesday indicating the U.S. is in a recession, this isn't surprising. The ECB is also meeting today to consider its move. Today, the Labor Department will report weekly initial jobless claims and the Commerce Department will release August factory orders. Regulators also extended the ban on short-selling shares of some 800 financial companies.

UBS (NYSE: UBS), which has been hard hit by the credit crisis, said Thursday it expects to return to profit in the third quarter after four quarters of losses. The bank has substantially reduced its exposure to U.S. commercial and residential mortgages. The bank wrote down more than $40 billion and raised close to $30 billion.

Mosaic (NYSE: MOS) shares are down about 20% in pre-market trading after it missed analyst estimates when it reported its fiscal first-quarter earnings.

Marriott International (NYSE: MAR) was expected to report earnings of 32 cents a share in the third quarter. The company reported 34 centsearnings per share excluding an 8 cents adjustment.

The story of ImClone Systems Inc. (NASDAQ: IMCL) in its endeavor to sell itself surely feels by now like a never-ending saga, with twists, derisive comments from management and even a mystery. I guess that with Carl Icahn at the helm it's not surprising; he would always try to get the best price he could.

After Icahn announced nearly a month ago that ImClone has a mystery suitor that would pay $70 a share to Bristol-Myers Squibb (NYSE: BMY)'s offer of $60 a share, today the mystery was unraveled and the suitor revealed. (I must admit I was somewhat skeptical, almost thinking this was some sort of tactic by Icahn to get to BMY, but he was serious.) While Pfizer Inc. (NYSE: PFE) has been the name most tossed around as the likely candidate, another name that's been cited -- Eli Lilly and Co. (NYSE: LLY) -- turned out to be the one.

As it was, after a rival buyer was revealed, Bristol indeed increased its bid for ImClone to $62 per share last week, but since Icahn insisted the unnamed large pharma company was willing to pay much more, he exchanged some very colorful comments with Bristol's chief.

The Wall Street Journal finally reported this afternoon it is Lilly that is in advanced talks to acquire ImClone for about $6.1 billion. There's no doubt Lilly would benefit from ImClone's one and only product, Erbitux -- a lucrative cancer drug. Also, as Lilly sees its drugs come off patent, and with its own poor pipeline of cancer drugs -- not to mention its recent troubles getting new drugs past the FDA -- this acquisition would make sense.

The deal's deadline is tonight. If Lilly indeed issues a formal offer, I bet Icahn hopes Bristol would increase its offer as not only does BMY already own about 17% of ImClone, it also co-markets Erbitux, and is simply seen by many as the natural buyer. I doubt we've seen the last of this story.

Today was another tiring day. Stocks gapped down lower and then managed to spend most of the day fighting in negative and positive territory. The ISM data on manufacturing this morning was atrocious and the worst since after the 2001 terror attacks. The Senate is expected to vote on a bailout plan tonight.

Below are today's closing bell levels:
DJIA 10,836.96 -13.70 -0.13%
NASDAQ 2,069.40 -22.48 -1.07%
S&P500 1,161.49 -4.87 -0.42%
10YR T-Bond 3.7680% -0.0590
52-week lows
Top Analyst Upgrades
Top Analyst Downgrades

General Electric Co. (NYSE: GE) had been down much worse today after an analyst downgrade raised further liquidity concerns. Then the announcement came that it was selling $12 billion stock to the public and $3 billion in preferred to Warren Buffett. Shares were down 3.4% at $42.15 in today's final minutes.

Citigroup Inc. (NYSE: C) rose on further hopes of a Senate bailout package and on higher FDIC deposit limits. It is also expected to price $10 Billion in stock tonight. Shares were up 11.5% at $22.86 in the final minutes of the day.

Stock futures dropped sharply Monday morning after the bailout plan was revealed Sunday and several banks in Europe were bailed out. U.S. investors are expected to react similar to stock markets around the word, which tumbled Monday following Washington's $700 billion bank bailout deal. The bailout may not be enough, and it will take a while to clean up the mess and restore confidence to financial markets. The economic reading due to be released today, August personal income and spending is not expected to affect markets much.

Three major banking bailouts were announced in Europe. 1) The Dutch-Belgian bank and insurance giant Fortis failed and was provided with a $16.4 billion lifeline by the governments of Belgium, the Netherlands and Luxembourg. 2) The British government nationalized mortgage lender Bradford & Bingley -- the second British bank to be taken under government control this year. 3) A consortium of German banks and regulators bailed out Hypo Real Estate Holding AG, in a deal worth billions of dollars.

Wachovia Corp. (NYSE: WB) - after WaMu's failure, the focus has shifted to Wachovia and at least two major banks, Citigroup Inc. (NYSE: C) and Wells Fargo & Co. (NYSE: WFC), were reportedly in talks Sunday to buy it. Wachovia shares are trading down 60% to $4 in pre-market action. C and WFC shares are down over 6.5% and 3.5% respectively in pre-market trade.

Today was nothing short of "Bailout Failure: Day 2 of the Siege" after Bernanke and Paulson both talked down the markets in the speech over the need for the bailout package on Capitol Hill. It is becoming the fear or the concern that many failures are just going to have to shake out of the system. The good news is that oil fell too after a record day into yesterday's futures expiration for the October contract. Bond yields also rose on fears that the Treasury is just going to print money for whatever bailout package it puts together.

Below are today's unofficial closing bell levels:
DJIA 10,851.30 -164.39 (-1.49%)
NASDAQ 2,155.34 -23.64 (-1.08%)
S&P500 1,189.96 -17.13 (-1.42%)
10YR T-Note 3.841% (+0.015%)
52-Week Lows
Analyst Upgrades
Analyst Downgrades

Air Products & Chemicals Inc. (NYSE: APD) lowered its guidance for the quarter. The company now sees its earnings in a range of $1.24 to $1.26 EPS, while First Call has the consensus estimate of $1.40 and its previous guidance was $1.37 to $1.42. It gave its one-time reasons, but this sounds more symptomatic than anything.

Circuit City Stores Inc. (NYSE: CC) announced that CEO Philip Schoonover was forced to resign amid nearly two-year's worth of troubles and management missteps that drove this company into the ground. Shares were indicated up over 5% early today, but traders sold the news as they just expect the numbers to get worse. Shares were down over 5% at $1.61 immediately before the close.

Citigroup Inc. (NYSE: C) was down over 4% at $19.20 in today's final miunutes. Part may be on bailout concerns, but Meredith Whitney of Oppenheimer cut key bank estimates again along with other money center banks.

General Electric Co. (NYSE: GE) was down almost 4.5% at $25 in the final minutes today although not on news out of the company itself. It seems that Merrill Lynch has finally figured out there is more turmoil in the consumer and financial sector. The brokerage firm downgraded its Buy rating to a lower Neutral rating.

ImClone Systems Inc. (NASDAQ: IMCL) was one of the few real winners with shares up over 6% at $63.11 in today's final minutes. This is after the acquisition offer has now been raised to a formal tender of $62 per share.

Stock futures are somewhat lower this morning, indicating another possible down start on Wall Street as investors await to hear Bernanke and Paulson explain the details of the $700 billion bailout plan. Meanwhile, after oil's record one-day gain Monday, it fell below $108 a barrel Tuesday. And yet another group, this time the National Retail Federation, said holiday sales are expected to grow at the slowest pace in six years for the obvious reasons from housing to job concerns.

Circuit City Stores Inc. (NYSE: CC) CEO Philip J. Schoonover is finally stepping down, no doubt to many releif sighs around the Street. James A. Marcum will replace the resigning CEO and Allen B. King will become Circuit City's new chairman. Shares are actually shooting up over 11% in pre-market trading.

Lennar Corp. (NYSE: LEN) reported a narrower third-quarter loss as it cut costs, but revenue fell by more than half amid a prolonged housing slump. The homebuilder's earnings were below estimates, while revenue beat analysts' number.

Bristol-Myers Squibb Co. (NYSE: BMY) sweetened its offer for ImClone Inc. (NASDAQ: IMCL) to $62 per share. Almost two weeks ago, though, Icahn said he had a $70 per share offer from an undisclosed company. If it wasn't an imaginary bid, it's hard to see why IMCL would go with BMY's offer. In the meantime, however, as the unidetified pharma examines IMCL, the latter keeps delaying giving an answer to BMY. IMCL shares are up over 6.5% to $63.25 in pre-market trading, indicating investors expect BMY's offer to be sweetened again.

ImClone Systems Inc. (NASDAQ: IMCL) had good results today, with shares closing up 6.7% at $67.94. The biotechnology company rejected Bristol-Myers Squibb (NYSE: BMY)'s offer to buy the remaining 83% of the company at $60 a share, saying it is considering a buyout offer worth $70 per share from an unidentified large pharmaceutical company. It seems that chairman Icahn has been busy.

To be sure, I was one of the skeptics when the billionaire investor last rejected BMY's offer, as was my colleague Doug McIntyre. But if this new offer is for real, then I must admit I underestimated him. Apparently, he "has been in talks with the chief executive of the pharmaceutical company that made the new offer, which would be worth about $6.1 billion." ImClone said it has not decided if the offer is adequate -- talk about playing hard ball all the way.

Bristol-Myers is ImClone's partner in selling its only product, the colon and head-and-neck cancer drug Erbitux. Analysts believe this would force BMY to offer $70 as well. A partnership between BMY and ImClone makes sense strategically. But I guess it all depends on who is the other pharmaceutical company BMY is competing with. Many pharma companies are losing sales to generic companies as their drugs go off patent, and without having much in the pipeline, but enough cash on their hands, any of them could be an interested buyer.

Some specific names mentioned by analysts include Sanofi-Aventis (NYSE: SNY), GlaxoSmithKline PLC (NYSE: GSK) and possibly AstraZeneca PLC (NYSE: AZN). Germany's Merck KGaA, which already sells Erbitux in some countries outside North America, is another likely candidate, as is Pfizer Inc. (NYSE: PFE), which has been trying to expand its portfolio of oncology drugs.

It's interesting that negotiations with the other company have been kept so tight, except for the price of course. BMY wins either way -- even if it can't get ImClone -- as it still holds 17% of BMY shares. Icahn, of course, would be a big winner too. Other options ImClone has been entertaining was spinning off the Erbitux division into a separate firm. The parent company would focus on developing drugs in its pipeline.

Bristol-Myers Squibb (NYSE: BMY) has made a $60 a share offer for the part of ImClone (NASDAQ: IMCL) that it does not already own. ImClone chairman Carl Icahn does not think tha$60 is high enough, despite ImClone trading below $40 in June. The offer seems like a pretty good deal, and since BMY owns 17% of ImClone , there is not likely to be another bidder.

According to The Wall Street Journal, ImClone's board appointed a committee to review last week's $60-a-share offer, but the biotechnology company said the board's "preliminary view is that offer substantially undervalues ImClone."

Icahn should take the money and run. Bristol-Myers clearly has the option to withdraw its bid and watch the stock drop back to $45. Holders of ImClone stock would likely get POed at Icahn, and is it any wonder?

It is not a perfect match, but the ImClone negotiations are starting to shape up the way Microsoft's (NASDAQ: MSFT) talks with Yahoo! (NASDAQ: YHOO) did. Microsoft needed Yahoo! for its internet strategy. No other company was going to pay a large premium for the portal's shares. When Microsoft walked away, Yahoo!'s share lost a third of their value.

Icahn has a history of pushing for a better deal. His batting average on recent investments is hardly perfect. He is not doing anyone, including himself, any favors by fighting with Bristol-Myers.

Douglas A. McIntyre is an editor at 247wallst.com.

In the News:

Your Money: McCain vs. Obama
See where the presidential candidates stand on the major economic issues like gas prices, taxes, mortgage crisis, jobs, health crisis and more.
Your Money: McCain vs. Obama - CNNMoney.com

If Only Martha Stewart Was a Little More Patient
If they only had been more patient investors of ImClone Systems, Martha Stewart and others might have done just fine, and avoided jail time. In a strange twist, ImClone -- the biotechnology company whose stock was dumped just before bad news was announced about an experimental cancer drug -- has received a multibillion-dollar takeover bid pegged to the success of that very same drug.
Once Dumped, ImClone Soars - NYTimes.com

In the News:
4 Companies With Strong Cash Flow
These four are in a good position to withstand the slowing economy. They include Boeing, IBM, Johnson & Johnson and VF Corp.
Four Companies With Strong Cash Flow - SmartMoney.com

Securing Your Dream Retirement
Planning for retirement takes as much time as planning a vacation. Plan the ultimate vacation. The key is making the right choices. Here is your guide to put you on the right path.
Control your destiny - Bankrate.com

Airlines Sell Frequent-Flier Miles for Fast Cash, Travelers Be Wary
Airlines searching for extra cash to survive their deepening financial crisis are finding out just how valuable their frequent-flier programs really are. Travelers, however, could see the value of their frequent-flier miles eroded by such deals, especially since all those extra miles will be hitting the market as airlines begin shrinking capacity dramatically.
Airlines sell frequent-flier miles for fast cash - USATODAY.com
In the News: Delta Redoes Mileage Plan for Its Fliers

MOST NOTEWORTHY: The North American Pipeline sector, Aeropostale and ImClone were today's noteworthy initiations:

• BMO Capital initiated the North American Pipeline sector with a Market Perform rating. El Paso Corp (NYSE:EP), Williams Companies (NYSE:WMB) and Spectra Energy (NYSE:SE) were initiated with Outperform ratings and CenterPoint Energy (NYSE:CNP) and AGL Resources (NYSE:ATG) ATG were assumed with Market Perform ratings.
  
• Friedman Billings believes Aeropostale (NYSE:ARO) has an impressive back-to-school floorset and that momentum should carry into the fall. Additionally, the firm, which initiated shares with an Outperform rating and $38 target, expects the company to buyback shares.
  
• Thomas Weisel believes ImClone (NASDAQ:IMCL) is attractively valued as Erbitux is positioned to capitalize on a number of label-expanding opportunities and that concerns of KRAS-related revenue loss in colorectal cancer and the clinical utility of FLEX lung cancer data are overstated. Shares were assumed with an Overweight rating and $50 target.

OTHER INITIATIONS:

• JMP Securities initiated Website Pros. inc. (NASDAQ:WWWW) and GSI Commerce (NASDAQ:GSIC) with Outperform ratings and target of $12 and $19, respectively.
  
• McAfee (NYSE:MFE) was assumed at Baird with an Outperform rating and $44 target.